血浆YKL-40与脑健康及痴呆的MRI、脑脊液和认知标志物的关联
该研究基于美国或欧洲4个社区队列,分析血浆YKL-40与MRI脑体积、认知及痴呆风险的关系。结果显示较高的血浆YKL-40水平与较小的全脑体积、较差的认知及痴呆发病风险升高相关,但与海马体积和白质高信号体积无关;在ACE脑脊液队列中,血浆与脑脊液YKL-40相关,且均与轻度认知障碍向痴呆转化相关。
要点
- 血浆YKL-40每升高1个标准差单位,全脑体积较小(β=-0.33)且认知较差(β=-0.04)。
- FHS队列中血浆YKL-40每升高1个标准差单位,痴呆发病风险增加64%(HR 1.64)。
- 血浆与脑脊液YKL-40相关(r=0.31),均与轻度认知障碍向痴呆转化相关。
核心结论
- 较高的血浆YKL-40水平与较低的全脑体积、较差的认知及痴呆发病相关。
- 血浆YKL-40可能有助于研究炎症及其治疗与痴呆风险的关联。
研究设计与样本
- 研究为美国或欧洲4个社区队列的横断面和前瞻性分析:年龄、基因/环境易感性-雷克雅未克研究、社区动脉粥样硬化风险研究、年轻成人冠状动脉风险发展研究和弗雷明汉心脏研究(FHS)。
- YKL-40由单一实验室使用Mesoscale Discovery从储存血浆中测定,水平经对数转换并在每个队列内标准化。
- 结局包括MRI全脑体积、海马体积、白质高信号体积占颅内体积百分比、神经心理测试衍生的总体认知复合评分(标准差单位[SDU])及痴呆发病风险。
- 在临床ACE脑脊液队列中重复验证痴呆关联,该队列也测定了脑脊液YKL-40。
主要发现
- MRI结局的荟萃分析纳入6,558名无痴呆参与者,认知分析纳入6,670名。
- 各队列中抽血先于MRI/认知评估最多10.6年,平均年龄范围50至76岁,男性占39%-48%。
- 随机效应荟萃分析中,对数转换YKL-40水平每增加1个SDU,与全脑体积较小(β=-0.33;95%CI -0.45至-0.22;p<0.0001)和认知较差(β=-0.04;95%CI -0.07至-0.02;p<0.01)相关,均经人口学变量调整。
- YKL-40水平与海马体积或白质高信号体积无关。
- FHS中,对数YKL-40水平每增加1个SDU,在中位随访5.8年中痴呆发病风险增加64%,经人口学变量调整(风险比1.64;95%CI 1.25-2.16;p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Higher YKL-40 levels in the CSF are a known biomarker of brain inflammation. We explored the utility of plasma YKL-40 as a biomarker for accelerated brain aging and dementia risk. METHODS: We performed cross-sectional and prospective analyses of 4 community-based cohorts in the United States or Europe: the Age, Gene/Environment Susceptibility-Reykjavik Study, Atherosclerosis Risk in the Communities study, Coronary Artery Risk Development in Young Adults study, and Framingham Heart Study (FHS). YKL-40 was measured from stored plasma by a single laboratory using Mesoscale Discovery with levels log transformed and standardized within each cohort. Outcomes included MRI total brain volume, hippocampal volume, and white matter hyperintensity volume (WMHV) as a percentage of intracranial volume, a general cognitive composite derived from neuropsychological testing (SD units [SDU]), and the risk of incident dementia. We sought to replicate associations with dementia in the clinic-based ACE csf cohort, which also had YKL-40 measured from the CSF. RESULTS: Meta-analyses of MRI outcomes included 6,558 dementia-free participants, and for analysis of cognition, 6,670. The blood draw preceded MRI/cognitive assessment by up to 10.6 years across cohorts. The mean ages ranged from 50 to 76 years, with 39%-48% male individuals. In random-effects meta-analysis of study estimates, each SDU increase in log-transformed YKL-40 levels was associated with smaller total brain volume (β = -0.33; 95% CI -0.45 to -0.22; p < 0.0001) and poorer cognition (β = -0.04; 95% CI -0.07 to -0.02; p < 0.01), following adjustments for demographic variables. YKL-40 levels did not associate with hippocampal volume or WMHV. In the FHS, each SDU increase in log YKL-40 levels was associated with a 64% increase in incident dementia risk over a median of 5.8 years of follow-up, following adjustments for demographic variables (hazard ratio 1.64; 95% CI 1.25-2.16; p < 0.001). In the ACE csf cohort, plasma and CSF YKL-40 were correlated (r = 0.31), and both were associated with conversion from mild cognitive impairment to dementia, independent of amyloid, tau, and neurodegeneration status. DISCUSSION: Higher plasma YKL-40 levels were associated with lower brain volume, poorer cognition, and incident dementia. Plasma YKL-40 may be useful for studying the association of inflammation and its treatment on dementia risk.
引用
- Pase MP, Himali JJ, Puerta R, et al. Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia. Neurology. 2024. PMID: 38290090. doi:10.1212/WNL.0000000000208075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。